Monitoring endogenous GPCRs: lessons for drug design
G protein-coupled receptors (GPCRs) are integral membrane proteins forming the fourth largest superfamily in the human genome. Many of these receptors play key physiological roles and several pathologies have been associated with receptor functional abnormalities. GPCRs therefore represent important...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2015 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (134 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993543672704498 |
---|---|
ctrlnum |
(CKB)3710000000824719 (oapen)https://directory.doabooks.org/handle/20.500.12854/53904 (EXLCZ)993710000000824719 |
collection |
bib_alma |
record_format |
marc |
spelling |
Dominique Massotte auth Monitoring endogenous GPCRs: lessons for drug design Monitoring endogenous GPCRs Frontiers Media SA 2015 1 electronic resource (134 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics G protein-coupled receptors (GPCRs) are integral membrane proteins forming the fourth largest superfamily in the human genome. Many of these receptors play key physiological roles and several pathologies have been associated with receptor functional abnormalities. GPCRs therefore represent important goals for drug design in pharmaceutical companies since they constitute the target of about one third of the drugs currently on the market. However, endogenous GPCRs are most often difficult to study because of a lack of tools to target them specifically and single out their response to physiological or drug-elicited stimulations. Hence, studies mostly focused on recombinant receptors expressed in a variety of cellular models that do not always closely reflect the receptor natural environment and often deal with levels of expression exceeding by far physiological ranges. Recent technological developments combining for example genetically modified animals and advanced imaging approaches have improved our ability to visualize endogenous GPCRs. To date, trailing receptor activation, subsequent intracellular redistribution, changes in signaling cascade up to integrated response to a drug-elicited stimulation is at hand though the impact of a physiological challenge on receptor dynamics remains a major issue. Data however suggest that the receptor may embrace a different fate depending on the type of stimulation in particular if sustained or repeated. This suggests that current drugs may only partially mimic the genuine response of the receptor and may explain, at least in part, their secondary effects. Commonalities and specificities between physiological and drug-induced activation can thus represent valuable guidelines for the design of future drugs. English opioid receptors G protein coupled receptors CGamP mice FLIM fluorescent knock-in mice receptor heteromerization Endogenous receptors cannabinoid receptors biased signaling Opiate tolerance 2-88919-651-8 |
language |
English |
format |
eBook |
author |
Dominique Massotte |
spellingShingle |
Dominique Massotte Monitoring endogenous GPCRs: lessons for drug design Frontiers Research Topics |
author_facet |
Dominique Massotte |
author_variant |
d m dm |
author_sort |
Dominique Massotte |
title |
Monitoring endogenous GPCRs: lessons for drug design |
title_full |
Monitoring endogenous GPCRs: lessons for drug design |
title_fullStr |
Monitoring endogenous GPCRs: lessons for drug design |
title_full_unstemmed |
Monitoring endogenous GPCRs: lessons for drug design |
title_auth |
Monitoring endogenous GPCRs: lessons for drug design |
title_alt |
Monitoring endogenous GPCRs |
title_new |
Monitoring endogenous GPCRs: lessons for drug design |
title_sort |
monitoring endogenous gpcrs: lessons for drug design |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2015 |
physical |
1 electronic resource (134 p.) |
isbn |
2-88919-651-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT dominiquemassotte monitoringendogenousgpcrslessonsfordrugdesign AT dominiquemassotte monitoringendogenousgpcrs |
status_str |
n |
ids_txt_mv |
(CKB)3710000000824719 (oapen)https://directory.doabooks.org/handle/20.500.12854/53904 (EXLCZ)993710000000824719 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Monitoring endogenous GPCRs: lessons for drug design |
container_title |
Frontiers Research Topics |
_version_ |
1787548875442094081 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02958nam-a2200397z--4500</leader><controlfield tag="001">993543672704498</controlfield><controlfield tag="005">20231214132852.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2015 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000824719</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/53904</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000824719</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dominique Massotte</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Monitoring endogenous GPCRs: lessons for drug design</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Monitoring endogenous GPCRs</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (134 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">G protein-coupled receptors (GPCRs) are integral membrane proteins forming the fourth largest superfamily in the human genome. Many of these receptors play key physiological roles and several pathologies have been associated with receptor functional abnormalities. GPCRs therefore represent important goals for drug design in pharmaceutical companies since they constitute the target of about one third of the drugs currently on the market. However, endogenous GPCRs are most often difficult to study because of a lack of tools to target them specifically and single out their response to physiological or drug-elicited stimulations. Hence, studies mostly focused on recombinant receptors expressed in a variety of cellular models that do not always closely reflect the receptor natural environment and often deal with levels of expression exceeding by far physiological ranges. Recent technological developments combining for example genetically modified animals and advanced imaging approaches have improved our ability to visualize endogenous GPCRs. To date, trailing receptor activation, subsequent intracellular redistribution, changes in signaling cascade up to integrated response to a drug-elicited stimulation is at hand though the impact of a physiological challenge on receptor dynamics remains a major issue. Data however suggest that the receptor may embrace a different fate depending on the type of stimulation in particular if sustained or repeated. This suggests that current drugs may only partially mimic the genuine response of the receptor and may explain, at least in part, their secondary effects. Commonalities and specificities between physiological and drug-induced activation can thus represent valuable guidelines for the design of future drugs.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">opioid receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">G protein coupled receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CGamP mice</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FLIM</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fluorescent knock-in mice</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">receptor heteromerization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Endogenous receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabinoid receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biased signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Opiate tolerance</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-651-8</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:34:59 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-08-13 16:41:26 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337414370004498&Force_direct=true</subfield><subfield code="Z">5337414370004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337414370004498</subfield></datafield></record></collection> |